ProCE Banner Activity

CE

Immune Checkpoint Inhibitors in the Treatment of Stage III NSCLC: A Primer for Managed Care Pharmacy

Multimedia
Watch this CPE-certified Webcast of a CCO symposium at AMCP 2018, where Mark M. Awad, MD, PhD; Sandra Cuellar, PharmD, BCOP; and Ali McBride, PharmD, MS, BCOP, FAzPA, review and discuss the latest data on immune checkpoint inhibitors for stage III NSCLC as they apply to pharmacists and managed care professionals.

Pharmacists : 1.50 contact {hours} ({0.15} CEUs)

Released: June 12, 2018

Expiration: June 11, 2019

No longer available for credit.

Share

Faculty

Mark M. Awad

Mark M. Awad, MD, PhD

Assistant Professor
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Sandra Cuellar

Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP

Clinical Oncology Pharmacist, UI Health
Clinical Associate Professor
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

Ali McBride

Ali McBride, PharmD, MS, BCOP, FAzPA

Clinical Coordinator
Department of Pharmacy
The University of Arizona Cancer Center
Tucson, Arizona

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by an educational grant from

AstraZeneca

Target Audience

This program is intended for pharmacists, managed care professionals, and healthcare providers who care for patients with non-small-cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review evidence-based strategies for the management of stage III NSCLC, considering systemic and local therapeutic modalities
  • Discuss the biologic rationale for using immune checkpoint inhibitors in early-stage cancers
  • Develop management strategies to address immune-mediated adverse events in patients receiving checkpoint inhibitors
  • Educate patients about the benefits and risks of using immune checkpoint inhibitor therapy and provide preventive strategies to reduce or ameliorate these toxicities
  • Explain the role of the oncology pharmacist in optimizing the use of checkpoint inhibitor therapy for unresectable stage III NSCLC and opportunities to advance oncology pharmacy services
  • Address challenging questions regarding the management of unresectable stage III NSCLC and discuss ways the managed care pharmacist can aid in the implementation of clinical pathways to deliver quality care

Disclosure

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Disclosure

Primary Author

Mark M. Awad, MD, PhD

Assistant Professor
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Mark M. Awad, MD, PhD, has no real or apparent conflicts of interest to report.

Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP

Clinical Oncology Pharmacist, UI Health
Clinical Associate Professor
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

Sandra Cuellar, PharmD, BCOP, has disclosed that she has received consulting fees from Eisai and fees for non-CME/CE services from Genentech.

Ali McBride, PharmD, MS, BCOP, FAzPA

Clinical Coordinator
Department of Pharmacy
The University of Arizona Cancer Center
Tucson, Arizona

Ali McBride, PharmD, MS, BCOP, FAzPA, has disclosed that he has served as a speaker for AstraZeneca.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008162-9999-18-165-H01-P

Type of Activity: Application

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 12, 2018, through June 11, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to educate pharmacists and managed care professionals about advances in the clinical management of patients with stage III non-small-cell lung cancer.